Publications by authors named "In Jeong Oh"
Article Synopsis
- A dual agonist of glucagon-like peptide (GLP)-1 and GLP-2 (GLP1/2-Fc) was tested in mice with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), conditions that currently lack FDA-approved treatments.
- * The treatment showed significant improvements by reducing body weight, glucose levels, liver fat, and inflammation, while enhancing liver fibrosis, insulin sensitivity, and gut health.
- * Fecal microbiota transplantation (FMT) was used to further explore the protective effects of GLP1/2-Fc, indicating that it may enhance the treatment's outcomes when combined with other therapies.*
Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but there have been few studies of gypenosides (Gyp). Particularly, no study on Gyp LXXV has been reported to date.
View Article and Find Full Text PDF